Format
Items per page
Sort by

Send to:

Choose Destination

Results: 7

Cited In for PubMed (Select 16185871)

1.

Basal cytokeratin as a potential marker of low risk of invasion in ductal carcinoma in situ.

Aguiar FN, Mendes HN, Cirqueira CS, Bacchi CE, Carvalho FM.

Clinics (Sao Paulo). 2013 May;68(5):638-43. doi: 10.6061/clinics/2013(05)010.

2.

Ductal carcinoma in situ: recent advances and future prospects.

Lambert K, Patani N, Mokbel K.

Int J Surg Oncol. 2012;2012:347385. doi: 10.1155/2012/347385. Epub 2012 May 17.

3.

Sentinel Lymph Node Biopsy in Pure DCIS: Is It Necessary?

Boler DE, Cabioglu N, Ince U, Esen G, Uras C.

ISRN Surg. 2012;2012:394095. doi: 10.5402/2012/394095. Epub 2012 May 14.

4.

Recent advances in the surgical care of breast cancer patients.

Mascaro A, Farina M, Gigli R, Vitelli CE, Fortunato L.

World J Surg Oncol. 2010 Jan 20;8:5. doi: 10.1186/1477-7819-8-5. Review.

5.

The pen and the scalpel: effect of diffusion of information on nonclinical variations in surgical treatment.

Griggs JJ, Sorbero ME, Ahrendt GM, Stark A, Heininger S, Gold HT, Schiffhauer LM, Dick AW.

Med Care. 2009 Jul;47(7):749-57. doi: 10.1097/MLR.0b013e31819748b3.

6.

Successful pregnancy after breast cancer therapy: dream or reality?

Kontzoglou K, Stamatakos M, Tsaknaki S, Goga H, Kostakis A, Safioleas M.

Int Semin Surg Oncol. 2009 Mar 2;6:7. doi: 10.1186/1477-7800-6-7.

7.

Contraindications of sentinel lymph node biopsy: are there any really?

Filippakis GM, Zografos G.

World J Surg Oncol. 2007 Jan 29;5:10. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk